Market Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson Joins First Industry-wide Call for New Collective Action to Address Antimicrobial Resistance

[PR Newswire] – NEW BRUNSWICK, N.J., Jan. 20, 2016 /PRNewswire/ — Johnson & Johnson (JNJ) today announced it has joined more than 80 companies and organizations in signing the Declaration on Combating Antimicrobial Resistance (AMR), an industry-wide call to action announced at the World Economic Forum in Davos, Switzerland. “We are pleased to be part of this important initiative to combat antimicrobial resistance,” said Paul Stoffels, M.D., Chief Scientific Officer and Worldwide Chairman, Pharmaceuticals, Johnson & Johnson. At Johnson & Johnson, our long-standing commitment to innovation in antimicrobial R&D is evident through our legacy products and our new efforts to support ongoing research. Read more on this. Johnson & Johnson (JNJ) , with a current value of $264.93B, began trading this morning at $96.10. During today’s session, JNJ traded between $94.53 to $97.28 with its 52-week range being $81.79 to $105.49. Johnson & Johnson (JNJ) shares are currently priced at 15.78x this year’s forecasted earnings, which makes them relatively expensive compared to the industry’s -2.14x earnings multiple for the same period. According to a consensus of 20 analysts, the earnings estimate of $1.42 per share would be $0.05 better than the year-ago quarter and a $0.00 sequential decrease. The full-year EPS estimate is $6.18 which would be a $0.21 setback than last year’s full-year earnings. The quarterly earnings estimate is based on a consensus revenue forecast of the current quarter of $17.88 Billion. If realized, that would be a 2.03% decrease over the year-ago quarter. More recently, Barclays downgraded JNJ from Overweight to Equal Weight (Jan 10, 2014). Previously, RBC Capital Mkts upgraded JNJ from Sector Perform to Outperform. When considering if the stock is under or overvalued, the average price target is $108.18, which is 12.57% above where the stock opened this morning. See more in (NYSE:JNJ) Similar Articles: Market Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson to cut about 3000 jobs Market Update: Johnson & Johnson (NYSE:JNJ) – U.S. justices reject Johnson & Johnson unit’s anti-psychotic drug appeal Market Update: Johnson & Johnson (NYSE:JNJ) – Johnson & Johnson to Participate in the 2015 Morgan Stanley Healthcare Conference